Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$1.54 -0.06 (-3.44%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$1.55
$1.65
50-Day Range
$1.60
$2.04
52-Week Range
$1.55
$3.09
Volume
24,208 shs
Average Volume
106,953 shs
Market Capitalization
$193.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.58
Consensus Rating
Hold

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 49% of companies evaluated by MarketBeat, and ranked 587th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Nautilus Biotechnology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nautilus Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Nautilus Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    0.47% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently decreased by 68.84%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.47% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nautilus Biotechnology has recently decreased by 68.84%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for NAUT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nautilus Biotechnology's insider trading history.
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Stock News Headlines

This Crypto Is Set to Explode in February
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

NAUT Stock Analysis - Frequently Asked Questions

Nautilus Biotechnology's stock was trading at $1.68 on January 1st, 2025. Since then, NAUT stock has decreased by 5.7% and is now trading at $1.5850.
View the best growth stocks for 2025 here
.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its quarterly earnings data on Tuesday, October, 29th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.04.

Top institutional shareholders of Nautilus Biotechnology include Bain Capital Life Sciences Investors LLC (1.40%), Geode Capital Management LLC (0.91%), Dimensional Fund Advisors LP (0.61%) and ArchPoint Investors (0.48%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld and Mary E Godwin.
View institutional ownership trends
.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

Last Earnings
10/29/2024
Today
2/21/2025
Next Earnings (Estimated)
2/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.58
High Stock Price Target
$6.00
Low Stock Price Target
$1.75
Potential Upside/Downside
+129.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.12 per share

Miscellaneous

Free Float
74,711,000
Market Cap
$195.87 million
Optionable
Optionable
Beta
1.21
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:NAUT) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners